ABL Bio_에이비엘바이오

ABL Bio is a leader in bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. ABL owns a productive set of innovative bispecific antibody platforms and pipelines. In the neurodegenerative disorder space, ABL Bio develops potential therapeutics for CNS-related diseases utilizing Grabody-B, which is designed to maximize BBB penetration. In the oncology area, Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety, and pipelines with Grabody-T such as ABL53, ABL111, ABL105, AB103, etc. ABL Bio is also currently focusing on new modality called ‘bispecific ADC’ that has both competitiveness of ADC and bispecific antibody.